<DOC>
	<DOCNO>NCT01126008</DOCNO>
	<brief_summary>This phase II trial evaluate efficacy concurrent chemoradiation therapy weekly docetaxel cisplatin combination regimen .</brief_summary>
	<brief_title>Concomitant Chemoradiotherapy ( CCRT ) With Weekly Docetaxel Cisplatin Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>Many study show superiority concurrent chemoradiotherapy radiotherapy locally advanced head neck cancer . Concurrent chemoradiotherapy high dose cisplatin universally use regimen . In large-scaled phase II trial , however , conduct European Organization Research Treatment Cancer ( EORTC ) , docetaxel ( 100mg/m2 ) plus cisplatin ( 75mg/ m2 ) every three week regimen produce improved survival , nonetheless significant limitation deliver full dose treatment due significant hematologic non-hematologic toxicity . Previously , show safety combination regimen weekly docetaxel cisplatin concurrent chemoradiation treatment phase I study . We determine MTD docetaxel 20mg/m2 weekly concurrently administer conventional fractionation RT weekly 20mg/m2 cisplatin .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically confirm squamous cell carcinoma head neck ( SCCHN ) one follow site : oral cavity , oropharynx , larynx , hypopharynx 2 . Unresectable Stage III ⅣB disease 3. previously untreated head &amp; Neck cancer chemotherapy radiotherapy 4 . 18 5 . Performance status ECOG 01 6 . Absolute neutrophil count ≥ 1,500/mm3 7 . Platelet count ≥ 75,000/mm3 8 . Hemoglobin &gt; 9.0 g/dL 9 . Bilirubin ≤ 1.5 time upper limit normal ( ULN ) 10 . AST ALT , alkaline phosphatase meeting 1 follow parameter : Alkaline phosphatase ≤ 1.5 time ULN AND AST ALT ≤ 5 time ULN Alkaline phosphatase ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 5 time ULN AND AST ALT ≤ ULN 11. serum creatinine ≤ 1.5 mg/dl creatinine clearance ≥ 60 ml/min 1 . Distant metastatic disease ( M1 ) 2 . Prior chemotherapy RT Head neck cancer 3 . Synchronous concurrent head neck primary tumor 4 . Lip , nasopharynx , nasal cavity , salivary gland , sinuses 5 . No invasive malignancy within past 3 year except nonmelanoma skin cancer papillary thyroid cancer 6 . Other concurrent illness would preclude study participation 7 . Other concurrent physical condition ( e.g. , infectious disease ) would preclude study participation 8. pregnant nursing 9 . Fertile patient must use effective contraception 3 month study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>locally advanced Squamous cell carcinoma</keyword>
</DOC>